Novo Nordisk is partnering with OpenAI to "bring new and better treatment options to patients faster," the Danish drugmaker said Tuesday. The partnership will enable Novo to better use AI to analyze complex datasets, identify promising new drugs, and reduce the time it takes for a medicine to move from the research stage to patient use, the company said in a statement. "There are millions of people living with obesity and diabetes who need treatment options, and we know there are therapies